ArticleCancer research2009
Differential destruction of stem cells: implications for targeted cancer stem cell therapy.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cancer resistance to immunotherapy: What is the role of cancer stem cells?Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response.Methods in molecular biology (Clifton, N.J.) · 2018Review
- Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells.Journal of experimental & clinical cancer research : CR · 2016Article
- Digitalization of a non-irradiated acute myeloid leukemia model.BMC systems biology · 2016Article
- miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1.Scientific reports · 2016Article
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.Frontiers in pharmacology · 2016Review
- Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells.Frontiers in pharmacology · 2016Review
- Article
- Effect of dedifferentiation on time to mutation acquisition in stem cell-driven cancers.PLoS computational biology · 2014Article
- Nonlinear growth kinetics of breast cancer stem cells: implications for cancer stem cell targeted therapy.Scientific reports · 2013Article
- Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors.Cellular oncology (Dordrecht, Netherlands) · 2012Review
- Article
- Stem cell niche dynamics: from homeostasis to carcinogenesis.Stem cells international · 2012Article
- Extinction models for cancer stem cell therapy.Mathematical biosciences · 2011Article
- Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.Molecular cancer therapeutics · 2011Article
- Resident stem cells and renal carcinoma.International journal of nephrology · 2011Article
- Quiescent fibroblasts exhibit high metabolic activity.PLoS biology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer stem cells represent a novel therapeutic target. The major challenge in targeting leukemic stem cells (LSC) is finding therapies that largely spare normal hematopoietic stem cells (HSC) while eradicating quiescent LSCs. We present a mathematical model to predict how selective a therapy must be to ensure that enough HSCs survive when LSCs have been eradicated. Stem cell population size is modeled as a birth-death process. This permits comparison of LSC and HSC eradication times under therapy and calculation of the number of HSCs at the time of LSC eradication for varied initial population sizes and stem cell death rates. We further investigate the effects of LSC quiescence and resistance mutations on our predictions. From a clinical point of view, our models suggest criteria by which cancer stem cell therapy safety can be assessed. We anticipate that in conjunction with experimental observation of cancer stem cell killing rates, our results will be useful in screening targeted therapies for both hematologic and solid tumor malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.